Nuwellis appoints Michael McCormick to board as Lead Independent Director; Warren Watson resigns

Nuwellis, Inc.

McCormick appointed Class I director effective June 1, 2023, as Lead Independent Director, Audit Committee member, and Nominating Committee Chair.
McCormick receives $45K annual retainer plus $10K Lead Director fee, $7.5K Audit Committee, $10K Nominating Chair.
Warren Watson resigned June 2, 2023, from board and all committees; no disagreement with company.
McCormick has 25+ years med device experience, formerly CEO of Osprey Medical and Anulex Technologies.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael McCormick

Lead Independent Director

NUWE · Nuwellis, Inc.

Effective: 2023-06-01
Filed: June 5, 2023, 7:59 PM ET

On May 30, 2023, the Board of Directors (the " Board ") of Nuwellis, Inc., a Delaware corporation (the " Company ") approved, effective as of June 1, 2023, the appointment of Michael McCormick to fill a vacancy in the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael McCormick was appointed as Lead Independent Director at Nuwellis, Inc..

Action: appointed
Role: Lead Independent Director

Exact text from the filing

On May 30, 2023, the Board of Directors (the " Board ") of Nuwellis, Inc., a Delaware corporation (the " Company ") approved, effective as of June 1, 2023, the appointment of Michael McCormick to fill a vacancy in the Board.

View on SEC.gov

Nuwellis, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-028397

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.